Alyeska Investment Group
ANAB icon

Alyeska Investment Group’s AnaptysBio ANAB Stock Holding History

Alyeska Investment Group’s Portfolio ANAB Stock Details ANAB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q1 		– Sell
-121,902
Closed -$7.78M – 373
2018
Q4 		$7.78M Sell
121,902
-38,098
-24% -$2.83M 0.11% 190
2018
Q3 		$16M Buy
+160,000
New +$13.3M 0.17% 146
2017
Q2 		– Sell
-52,250
Closed -$1.45M – 451
2017
Q1 		$1.45M Buy
+52,250
New +$1.22M 0.01% 415

Other funds holding ANAB

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
FM
Frazier Management Seattle, Washington $1.12M AUM 151.58% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
O
OppenheimerFunds New York $80.4B AUM 15.1% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Alyeska Investment Group's ANAB Position: Q1 2019 in Review

Alyeska Investment Group sold out of AnaptysBio (ANAB) in Q1 2019, closing a stake of 121,902 shares — an estimated $7.78M sold.

Alyeska Investment Group first reported a position in ANAB in Q1 2017 and held it in 3 quarters. The position peaked at $16M in Q3 2018. 129 funds tracked by Wall St. Rank hold ANAB as of Q1 2019.

  • Alyeska Investment Group reported no remaining AnaptysBio position as of Q1 2019 after selling out during the quarter.
  • Alyeska Investment Group sold 121,902 AnaptysBio shares in Q1 2019, an estimated $7.78M.
  • Alyeska Investment Group first reported a position in AnaptysBio in Q1 2017 and held it in 3 quarters.
  • Alyeska Investment Group's AnaptysBio position peaked at $16M in Q3 2018.
  • 129 funds tracked by Wall St. Rank held AnaptysBio as of Q1 2019.

Based on Alyeska Investment Group's 13F filing for Q1 2019, filed 15 May 2019.